This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory illness | 112 |
acute respiratory | 103 |
united states | 74 |
infectious diseases | 67 |
respiratory tract | 64 |
respiratory syndrome | 60 |
severe acute | 55 |
open forum | 53 |
novel coronavirus | 50 |
respiratory syncytial | 49 |
hospitalized patients | 49 |
coronavirus disease | 48 |
syncytial virus | 48 |
public health | 44 |
clinical trials | 44 |
severe covid | 41 |
forum infect | 40 |
dis doi | 40 |
cord uid | 40 |
doc id | 40 |
infect dis | 40 |
within days | 39 |
pregnant women | 39 |
supplementary table | 39 |
clinical characteristics | 37 |
logistic regression | 36 |
risk factors | 36 |
potential conflicts | 36 |
respiratory viruses | 36 |
african american | 35 |
lower respiratory | 34 |
chain reaction | 34 |
syndrome coronavirus | 34 |
polymerase chain | 34 |
severe disease | 33 |
health care | 32 |
specimen collection | 30 |
febrile hrv | 29 |
hemophagocytic lymphohistiocytosis | 27 |
respiratory pathogen | 27 |
statin treatment | 27 |
american patients | 26 |
symptom onset | 26 |
time pcr | 26 |
influenza vaccine | 26 |
dna levels | 26 |
respiratory viral | 26 |
south africa | 25 |
among patients | 25 |
intensive care | 25 |
virus infection | 25 |
ofaa sha | 25 |
hrv respiratory | 25 |
ofid ofaa | 25 |
statistically significant | 24 |
infection prevention | 24 |
tested positive | 23 |
icu admission | 23 |
clinical trial | 23 |
tract infections | 23 |
controlled trial | 23 |
health workers | 22 |
children years | 22 |
repeat testing | 22 |
middle east | 22 |
emergency department | 22 |
east respiratory | 22 |
viral infections | 21 |
antibody responses | 21 |
supportive care | 21 |
pcr testing | 21 |
pandemic influenza | 21 |
patients hospitalized | 21 |
increased risk | 21 |
randomized controlled | 21 |
upper respiratory | 21 |
rsv illness | 21 |
hospital admission | 20 |
antimicrobial stewardship | 20 |
heart failure | 20 |
white patients | 20 |
personal protective | 20 |
protective equipment | 20 |
clinical data | 20 |
respiratory infection | 20 |
respiratory pathogens | 20 |
infectious disease | 19 |
lung transplantation | 19 |
adverse events | 19 |
review board | 19 |
medically attended | 19 |
institutional review | 19 |
disease severity | 19 |
respiratory virus | 19 |
icmje form | 19 |
pulmonary disease | 19 |
healthcare workers | 19 |
acquired pneumonia | 18 |
medical center | 18 |
first days | 18 |
parainfluenza virus | 18 |
years old | 18 |
antibiotic use | 18 |
vitro activity | 18 |
obstructive pulmonary | 17 |
world health | 17 |
statistical significance | 17 |
systematic review | 17 |
confidence interval | 17 |
chronic obstructive | 17 |
exclusion criteria | 17 |
influenza virus | 17 |
nucleic acid | 17 |
patients infected | 17 |
patients receiving | 17 |
among adults | 17 |
new york | 17 |
health organization | 17 |
lung disease | 17 |
observational study | 17 |
supplemental table | 17 |
disease control | 17 |
barr virus | 17 |
influenza season | 17 |
respiratory disease | 17 |
among children | 17 |
high risk | 17 |
study period | 17 |
cohort study | 16 |
cell culture | 16 |
acute kidney | 16 |
viral shedding | 16 |
kidney injury | 16 |
received remdesivir | 16 |
editors consider | 16 |
human coronavirus | 16 |
pui testing | 16 |
consider relevant | 16 |
dose group | 16 |
virus infections | 15 |
transcription polymerase | 15 |
antigen receptor | 15 |
elderly subjects | 15 |
clinical presentation | 15 |
performed using | 15 |
hubei province | 15 |
mg dl | 15 |
care unit | 15 |
chimeric antigen | 15 |
interquartile range | 15 |
age groups | 15 |
birth outcomes | 15 |
within hours | 15 |
mechanical ventilation | 15 |
cell therapy | 15 |
piv type | 15 |
infection density | 15 |
viral load | 15 |
febrile respiratory | 15 |
test results | 15 |
medical students | 14 |
piv types | 14 |
infection among | 14 |
confirmed cases | 14 |
viral rna | 14 |
asymptomatic screening | 14 |
clinical improvement | 14 |
adverse birth | 14 |
months post | 14 |
birth weight | 14 |
case series | 14 |
repeat pui | 14 |
significantly higher | 14 |
infection control | 14 |
median time | 14 |
previous studies | 14 |
significant differences | 14 |
tract infection | 14 |
respiratory infections | 14 |
young adults | 13 |
human metapneumovirus | 13 |
ed visit | 13 |
study population | 13 |
informed consent | 13 |
forum infectious | 13 |
adult patients | 13 |
medical records | 13 |
older adults | 13 |
ccl mcp | 13 |
confirmed covid | 13 |
incubation period | 13 |
sore throat | 13 |
lopinavir ritonavir | 13 |
market forces | 13 |
days post | 13 |
reactive protein | 13 |
influenza pandemic | 13 |
mp treatment | 13 |
community cohort | 13 |
per year | 12 |
critically ill | 12 |
nonsevere group | 12 |
ill patients | 12 |
dose groups | 12 |
data provided | 12 |
drug administration | 12 |
viral clearance | 12 |
hev infection | 12 |
usual care | 12 |
congestive heart | 12 |
respiratory symptoms | 12 |
gestational age | 12 |
medical record | 12 |
compassionate use | 12 |
observational studies | 12 |
respiratory distress | 12 |
cases per | 12 |
id fellows | 12 |
treated patients | 12 |
severe group | 12 |
home specimen | 12 |
exposed hcws | 12 |
coronavirus infection | 12 |
influenza vaccines | 12 |
sole responsibility | 12 |
attended rsv | 11 |
healthcare system | 11 |
sample size | 11 |
human rhinovirus | 11 |
supplementary materials | 11 |
diseases online | 11 |
financial support | 11 |
antiviral activity | 11 |
throat swab | 11 |
hospital admissions | 11 |
viral respiratory | 11 |
present study | 11 |
discharged alive | 11 |
twice daily | 11 |
regression models | 11 |
health system | 11 |
positive patients | 11 |
rsv infection | 11 |
index case | 11 |
testing positive | 11 |
common cause | 11 |
requiring hospitalization | 11 |
corresponding author | 11 |
rickettsia conorii | 11 |
home isolation | 11 |
reverse transcription | 11 |
care workers | 11 |
less likely | 11 |
control group | 11 |
chronic lung | 11 |
respiratory specimens | 11 |
chart review | 11 |
posted materials | 11 |
regression model | 11 |
lbw infants | 11 |
cytokine release | 10 |
clinical features | 10 |
severe respiratory | 10 |
clinical outcomes | 10 |
treatment groups | 10 |
see supplementary | 10 |
turnaround time | 10 |
continuous variables | 10 |
spotted fever | 10 |
baseline characteristics | 10 |
american college | 10 |
diagnostic stewardship | 10 |
multiplex testing | 10 |
saudi arabia | 10 |
acute rejection | 10 |
whole blood | 10 |
illness episode | 10 |
contact tracing | 10 |
close contact | 10 |
human immunodeficiency | 10 |
reported conflicts | 10 |
randomized clinical | 10 |
social distancing | 10 |
median age | 10 |
national institute | 10 |
risk factor | 10 |
pathogen panel | 10 |
factors associated | 10 |
cd car | 10 |
influenza viruses | 10 |
metagenomic sequencing | 10 |
population density | 10 |
release syndrome | 10 |
invasive mv | 10 |
study design | 10 |
pregnant persons | 10 |
infants born | 10 |
immunodeficiency virus | 10 |
patients received | 10 |
persistent symptoms | 9 |
ebola virus | 9 |
universal masking | 9 |
renal disease | 9 |
sibu hospital | 9 |
day mortality | 9 |
distress syndrome | 9 |
predictive value | 9 |
antibiotic prescription | 9 |
dromedary camels | 9 |
three patients | 9 |
infected patients | 9 |
hospital system | 9 |
cardiopulmonary disease | 9 |
statin use | 9 |
time period | 9 |
case report | 9 |
treatment options | 9 |
adults hospitalized | 9 |
ad vaccine | 9 |
primary endpoint | 9 |
hospital length | 9 |
primary care | 9 |
illness onset | 9 |
like illness | 9 |
unfavorable evolution | 9 |
transplant recipients | 9 |
ct values | 9 |
online survey | 9 |
coronavirus infections | 9 |
infectious complications | 9 |
viral transport | 9 |
data collection | 9 |
teno virus | 9 |
study participants | 9 |
respiratory panel | 9 |
torque teno | 9 |
cardiovascular disease | 9 |
significant difference | 9 |
infectious events | 9 |
reported comorbidities | 9 |
among hospitalized | 9 |
severe pneumonia | 9 |
gastrointestinal symptoms | 9 |
seasonal incidence | 9 |
laboratory testing | 9 |
emerging infectious | 8 |
data analysis | 8 |
aseptic meningitis | 8 |
supply chain | 8 |
cytokine storm | 8 |
health emergency | 8 |
subjects achieving | 8 |
rp testing | 8 |
time reverse | 8 |
febrile illness | 8 |
lung transplant | 8 |
differential diagnosis | 8 |
kapit hospitals | 8 |
nasopharyngeal swab | 8 |
viral pathogens | 8 |
regression analysis | 8 |
piv infection | 8 |
hku infection | 8 |
day post | 8 |
corticosteroid therapy | 8 |
hi titer | 8 |
viral coinfection | 8 |
influenza immunization | 8 |
socioeconomic status | 8 |
vital signs | 8 |
study enrollment | 8 |
favorable evolution | 8 |
virus detected | 8 |
remdesivir trial | 8 |
cox proportional | 8 |
inclusion criteria | 8 |
case subject | 8 |
associated sari | 8 |
kidney disease | 8 |
may also | 8 |
home testing | 8 |
latinx patients | 8 |
hi titers | 8 |
immune system | 8 |
supplemental oxygen | 8 |
samples collected | 8 |
safety data | 8 |
hospitalization among | 8 |
data exist | 8 |
fungal infections | 8 |
treatment group | 8 |
elderly population | 8 |
categorical variables | 8 |
generation sequencing | 8 |
serious outcomes | 8 |
cerebrospinal fluid | 8 |
lymphoblastic leukemia | 8 |
care testing | 8 |
proportional hazards | 8 |
corticosteroid treatment | 8 |
nasopharyngeal swabs | 8 |
confirmed rsv | 8 |
confirmed influenza | 8 |
older age | 8 |
computed tomography | 8 |
post hoc | 8 |
univariate analysis | 8 |
electronic medical | 8 |
bone marrow | 7 |
pediatric patients | 7 |
human coronaviruses | 7 |
bacterial infection | 7 |
secondary outcomes | 7 |
influenza vaccination | 7 |
antibody response | 7 |
written consent | 7 |
observed incidence | 7 |
study arms | 7 |
died within | 7 |
age group | 7 |
influenza test | 7 |
remdesivir use | 7 |
safety profile | 7 |
odds ratio | 7 |
antimicrobial use | 7 |
antibiotic stewardship | 7 |
breastfeeding persons | 7 |
modeling paradigm | 7 |
mediterranean spotted | 7 |
pcr assay | 7 |
human parainfluenza | 7 |
acute lymphoblastic | 7 |
randomized trial | 7 |
free days | 7 |
outpatient setting | 7 |
oxygen requirements | 7 |
nasal swabs | 7 |
received supportive | 7 |
confirmed sars | 7 |
previously described | 7 |
ng ml | 7 |
propensity score | 7 |
reach statistical | 7 |
acute rejections | 7 |
patient care | 7 |
time rt | 7 |
previously published | 7 |
seir models | 7 |
antiviral therapy | 7 |
antibiotic prescribing | 7 |
test result | 7 |
inpatient setting | 7 |
systemic reactions | 7 |
rapid multiplex | 7 |
adult population | 7 |
vaccine effectiveness | 7 |
multiplex real | 7 |
viral etiology | 7 |
previously reported | 7 |
sample collection | 7 |
included patients | 7 |
confidence intervals | 7 |
large number | 7 |
critical care | 7 |
sari cases | 7 |
tract illness | 7 |
swab samples | 7 |
among pregnant | 7 |
seir model | 7 |
rsv cases | 7 |
convalescent plasma | 7 |
patient consent | 7 |
exact test | 7 |
higher expression | 7 |
one patient | 7 |
health systems | 7 |
viral genome | 7 |
clinical signs | 7 |
mental health | 7 |
chronic diseases | 7 |
low birth | 7 |
replacement therapy | 7 |
invasive mechanical | 7 |
ltec values | 7 |
control arm | 7 |
medical conditions | 7 |
body mass | 7 |
coronavirus hku | 7 |
illness among | 7 |
id practitioners | 7 |
pcr test | 7 |
national health | 7 |
bacterial infections | 7 |
dose formulation | 7 |
university hospital | 7 |
global health | 7 |
testing results | 7 |
statistical analysis | 7 |
mass index | 7 |
national institutes | 7 |
mg kg | 7 |
immunosuppressive treatment | 7 |
ec values | 7 |
solid organ | 7 |
kapit hospital | 7 |
antibody titers | 7 |
mouth twice | 7 |
also found | 7 |
seek testing | 7 |
least one | 6 |
id specialists | 6 |
ml min | 6 |
immunosuppressive therapy | 6 |
outcomes among | 6 |
systemic corticosteroids | 6 |
hi antibody | 6 |
hematopoietic stem | 6 |
serious outcome | 6 |
positive predictive | 6 |
electronic health | 6 |
net state | 6 |
protective effect | 6 |
missing data | 6 |
internal medicine | 6 |
hazard ratio | 6 |
best practices | 6 |
filmarray respiratory | 6 |
transport media | 6 |
avian influenza | 6 |
rapid rp | 6 |
illness due | 6 |
mortality rate | 6 |
social media | 6 |
clinical decision | 6 |
chest ct | 6 |
respiratory failure | 6 |
determine whether | 6 |
inflammatory markers | 6 |
diseases society | 6 |
viral pathogen | 6 |
significantly associated | 6 |
hazards models | 6 |
existing comorbidities | 6 |
licensure criteria | 6 |
associated hlh | 6 |
higher among | 6 |
sensitivity analysis | 6 |
antimicrobial prophylaxis | 6 |
clinical symptoms | 6 |
use authorization | 6 |
cell transplantation | 6 |
military trainees | 6 |
severe cases | 6 |
home saliva | 6 |
chronic kidney | 6 |
term care | 6 |
potential role | 6 |
first test | 6 |
hrv infection | 6 |
male gender | 6 |
throat swabs | 6 |
general population | 6 |
first hours | 6 |
without febrile | 6 |
supplementary data | 6 |
np swab | 6 |
stem cell | 6 |
high prevalence | 6 |
care facilities | 6 |
neonatal outcomes | 6 |
time points | 6 |
adult subjects | 6 |
infected pneumonia | 6 |
mean ttv | 6 |
positive results | 6 |
medical centers | 6 |
positive adults | 6 |
spectrum antiviral | 6 |
soft tissue | 6 |
acute lower | 6 |
preliminary report | 6 |
descriptive statistics | 6 |
hospitalized children | 6 |
medical school | 6 |
untreated case | 6 |
severe complications | 6 |
infected individuals | 6 |
psychological status | 6 |
pneumonia requiring | 6 |
combination therapy | 6 |
air force | 6 |
hospital discharge | 6 |
limited data | 6 |
applied biosystems | 6 |
received antibiotics | 6 |
lymphocyte count | 6 |
medical care | 6 |
clinical course | 6 |
multivariate logistic | 6 |
patients required | 6 |
metabolic disease | 6 |
asian american | 6 |
death within | 6 |
age years | 6 |
personal variables | 6 |
hong kong | 6 |
severe lower | 6 |
infections among | 6 |
clinical care | 6 |
square test | 6 |
calculated using | 6 |
clinical outcome | 6 |
diagnosis codes | 6 |
much higher | 6 |
positive samples | 6 |
two weeks | 6 |
several limitations | 6 |
per dose | 6 |
patients may | 6 |
first report | 6 |
health commission | 6 |
subject died | 6 |
among infants | 6 |
february th | 6 |
positive test | 6 |
avoidance behaviors | 6 |
cell count | 6 |
parainfluenza viruses | 6 |
primary outcome | 6 |
viral loads | 6 |
controlled trials | 6 |
multivariable logistic | 6 |
commercially available | 6 |
household size | 6 |
human adenovirus | 6 |
dna load | 6 |
chronic hepatitis | 6 |
emergency response | 6 |
potential benefit | 6 |
psychological distress | 6 |
antibiotic resistance | 6 |
emergency use | 6 |
patient safety | 6 |
york city | 6 |
tract disease | 6 |
immune response | 6 |
common cold | 6 |
local camels | 6 |
chronic metabolic | 6 |
initial test | 6 |
young children | 6 |
hand hygiene | 6 |
specific antibody | 5 |
described previously | 5 |
cell acute | 5 |
biofire filmarray | 5 |
patients requiring | 5 |
clinical findings | 5 |
vaccine formulation | 5 |
viral pneumonia | 5 |
composite primary | 5 |
matched sample | 5 |
respiratory illnesses | 5 |
hospital course | 5 |
hrv febrile | 5 |
outcomes included | 5 |
foster city | 5 |
patients due | 5 |
clinical utility | 5 |
microbiology laboratory | 5 |
million cases | 5 |
patient population | 5 |
significant risk | 5 |
control measures | 5 |
phase ii | 5 |
id experts | 5 |
time data | 5 |
among women | 5 |
cycle threshold | 5 |
common symptoms | 5 |
coronavirus pneumonia | 5 |
negative controls | 5 |
albumin level | 5 |
associated pneumonia | 5 |
related illness | 5 |
months postintervention | 5 |
solicited local | 5 |
close contacts | 5 |
urinary tract | 5 |
multirespiratory pathogen | 5 |
healthy adult | 5 |
south korea | 5 |
occurred within | 5 |
recovery trial | 5 |
tissue infections | 5 |
different types | 5 |
window period | 5 |
rhinovirus illness | 5 |
selection bias | 5 |
viral panel | 5 |
cmv viremia | 5 |
symptomatic patients | 5 |
coronavirus testing | 5 |
death among | 5 |
newly diagnosed | 5 |
antimicrobial prescribing | 5 |
cox regression | 5 |
sars coronavirus | 5 |
suspected covid | 5 |
one hundred | 5 |
stewardship programs | 5 |
nasopharyngeal samples | 5 |
care providers | 5 |
per days | 5 |
surveillance data | 5 |
vaccination status | 5 |
operating margins | 5 |
standard deviation | 5 |
four days | 5 |
nat positive | 5 |
repeat test | 5 |
severe crs | 5 |
influenza hospitalization | 5 |
protective behaviors | 5 |
negative test | 5 |
academic medical | 5 |
microsoft excel | 5 |
exam findings | 5 |
care system | 5 |
delayed return | 5 |
duke university | 5 |
literature review | 5 |
pathogen data | 5 |
poor outcomes | 5 |
nervous system | 5 |
interval ci | 5 |
first month | 5 |
cause death | 5 |
hrv illness | 5 |
household income | 5 |
data included | 5 |
skin manifestations | 5 |
guangzhou eighth | 5 |
retrospective observational | 5 |
wilcoxon test | 5 |
nonsevere disease | 5 |
mass general | 5 |
creatinine clearance | 5 |
pneumonia etiology | 5 |
group compared | 5 |
transplant recipient | 5 |
viral replication | 5 |
primary composite | 5 |
results may | 5 |
molecular evidence | 5 |
stewardship program | 5 |
virus disease | 5 |
patients discharged | 5 |
among individuals | 5 |
mild disease | 5 |
clinical benefit | 5 |
us food | 5 |
military recruit | 5 |
infection rates | 5 |
median duration | 5 |
th week | 5 |
hku infections | 5 |
positive conversion | 5 |
advanced age | 5 |
severe influenza | 5 |
invasive fungal | 5 |
well described | 5 |
organ transplant | 5 |
sought care | 5 |
clinical practice | 5 |
maternal influenza | 5 |
catchment area | 5 |
antibiotic prescriptions | 5 |
molecular tests | 5 |
study may | 5 |
type infection | 5 |
kidney replacement | 5 |
single center | 5 |
healthcare settings | 5 |
pcr confirmed | 5 |
organ failure | 5 |
available data | 5 |
care arm | 5 |
will require | 5 |
retrospective cohort | 5 |
therapeutic interventions | 5 |
ccl mip | 5 |
positive influenza | 5 |
illness episodes | 5 |
digital pcr | 5 |
ofid ofx | 5 |
infections per | 5 |
virus subtype | 5 |
breastfeeding women | 5 |
increased infection | 5 |
comorbid conditions | 5 |
per population | 5 |
antibody titer | 5 |
relative risk | 5 |
first months | 5 |
reference standard | 5 |
pcr assays | 5 |
urgently needed | 5 |
new antibiotic | 5 |
medical history | 5 |
positive tests | 5 |
cohort studies | 5 |
significantly longer | 5 |
dry cough | 5 |
chmp criteria | 5 |
inhaled corticosteroids | 5 |
ofx sha | 5 |
last menstrual | 5 |
heart disease | 5 |
even though | 5 |
antibiotic treatment | 5 |
chest computed | 5 |
clinical diagnosis | 5 |
nxtag respiratory | 5 |
patients enrolled | 5 |
achieving seroconversion | 5 |
hospital death | 5 |
case reports | 5 |
molecular assays | 5 |
positive cases | 5 |
positive specimens | 5 |
authors report | 5 |
serological testing | 5 |
routine clinical | 5 |
among us | 5 |
prolonged symptom | 5 |
general brigham | 5 |
least days | 4 |
mg daily | 4 |
total nucleic | 4 |
diagnostic tests | 4 |
analyzed using | 4 |
european organization | 4 |
mortality worldwide | 4 |
pui test | 4 |
septic shock | 4 |
pathogen testing | 4 |
care units | 4 |
higher risk | 4 |
underlying illness | 4 |
prospective cohort | 4 |
vertical transmission | 4 |
leading cause | 4 |
cells mm | 4 |
receiving lpv | 4 |
hoc analysis | 4 |
interventional clinical | 4 |
developed covid | 4 |
appropriate antibiotic | 4 |
military recruits | 4 |
reported pre | 4 |
mortality rates | 4 |
low prevalence | 4 |
clinical presentations | 4 |
onset date | 4 |
ofid ofz | 4 |
small sample | 4 |
broad spectrum | 4 |
data suggest | 4 |
higher rates | 4 |
fold increased | 4 |
trend toward | 4 |
large study | 4 |
children aged | 4 |
molecular epidemiology | 4 |
bronchoalveolar lavage | 4 |
drug shortages | 4 |
hiv serostatus | 4 |
human enterovirus | 4 |
matched samples | 4 |
recently published | 4 |
top talent | 4 |
may help | 4 |
face shield | 4 |
sum test | 4 |
systemic inflammation | 4 |
hospital stay | 4 |
supply chains | 4 |
acute care | 4 |
assessed using | 4 |
weeks apart | 4 |
virus type | 4 |
induction therapy | 4 |
peripheral blood | 4 |
outpatient clinics | 4 |
gene expression | 4 |
genome sequencing | 4 |
room air | 4 |
study protocol | 4 |
study procedures | 4 |
tested negative | 4 |
screening tests | 4 |
numerical variables | 4 |
repeat asymptomatic | 4 |
record abstraction | 4 |
based testing | 4 |
healthcare systems | 4 |
testing compared | 4 |
based specimen | 4 |
excluded pregnant | 4 |
potential treatment | 4 |
prognostic factors | 4 |
symptom duration | 4 |
required hospitalization | 4 |
hospitalized latinx | 4 |
infectious threats | 4 |
smoking status | 4 |
prior hct | 4 |
rate ratios | 4 |
sas institute | 4 |
study patients | 4 |
us military | 4 |
false positive | 4 |
clinical evolution | 4 |
loading dose | 4 |
health worker | 4 |
days prior | 4 |
time frame | 4 |
point estimate | 4 |
requiring supplemental | 4 |
pcr system | 4 |
recent years | 4 |
contact time | 4 |
urgent care | 4 |
military training | 4 |
inflammatory parameters | 4 |
contact history | 4 |
human influenza | 4 |
reproductive age | 4 |
effect size | 4 |
adjusted odds | 4 |
students participated | 4 |
therapeutic efficacy | 4 |
different countries | 4 |
two studies | 4 |
inpatient testing | 4 |
retrospective analysis | 4 |
mp group | 4 |
ofz sha | 4 |
trainees presenting | 4 |
initial negative | 4 |
sputum production | 4 |
central nervous | 4 |
enrollment visit | 4 |
clinical samples | 4 |
chest imaging | 4 |
careful consideration | 4 |
antimicrobial agents | 4 |
metagenomic next | 4 |
first two | 4 |
np sars | 4 |
decreased albumin | 4 |
repeat screening | 4 |
igg levels | 4 |
neutralizing antibody | 4 |
written informed | 4 |
ebola outbreak | 4 |
exposed hcw | 4 |
ifa titer | 4 |
antiviral treatment | 4 |
diseases pharmacists | 4 |
therapeutic strategies | 4 |
enrolled subjects | 4 |
immunogenicity outcomes | 4 |
mg iv | 4 |
digital droplet | 4 |
median household | 4 |
confirmed infection | 4 |
public response | 4 |
pneumonia among | 4 |
postpartum period | 4 |
decision making | 4 |
global burden | 4 |
fold increase | 4 |
analysis indicated | 4 |
first study | 4 |
healthcare institutions | 4 |
lymphodepleting chemotherapy | 4 |
id training | 4 |
care group | 4 |
cov infection | 4 |
influenza seasons | 4 |
first week | 4 |
treatment guide | 4 |
local group | 4 |
nontreatment group | 4 |
excluded due | 4 |
binary logistic | 4 |
emerging infections | 4 |
oxygen needs | 4 |
zip codes | 4 |
positive conversions | 4 |
day follow | 4 |
ed patients | 4 |
adjusted model | 4 |
symptomatic persons | 4 |
reference cases | 4 |
ethnic groups | 4 |
laboratory values | 4 |
imported camels | 4 |
study suggest | 4 |
standard care | 4 |
serious clinical | 4 |
distribute respiratory | 4 |
testing methods | 4 |
clinical information | 4 |
individual patients | 4 |
enhanced surveillance | 4 |
low risk | 4 |
unfavorable outcome | 4 |
blood cell | 4 |
isolation precautions | 4 |
respiratory support | 4 |
reported cases | 4 |
uninfected children | 4 |
hospital mortality | 4 |
rapid point | 4 |
infections may | 4 |
diagnostic test | 4 |
molecular detection | 4 |
adjusted hr | 4 |
tacrolimus toxicity | 4 |
patients without | 4 |
readily available | 4 |
collection options | 4 |
infant mortality | 4 |
rhinovirus infections | 4 |
cutaneous manifestations | 4 |
testing modalities | 4 |
stewardship strategies | 4 |
fetal neonatal | 4 |
without hrv | 4 |
infection risk | 4 |
wide spectrum | 4 |
significant reduction | 4 |
hospital personnel | 4 |
suspected cases | 4 |
present case | 4 |
bal samples | 4 |
attended respiratory | 4 |
significant impact | 4 |
febrile rhinovirus | 4 |
viruses detected | 4 |
sample sizes | 4 |
pathogen molecular | 4 |
guide diagnostic | 4 |
asymptomatic patients | 4 |
winter seasons | 4 |
medical education | 4 |
haemophagocytic syndrome | 4 |
care provider | 4 |
acute upper | 4 |
among adult | 4 |
family members | 4 |
solicited reactions | 4 |
test positive | 4 |
overall incidence | 4 |
rhinovirus infection | 4 |
data regarding | 4 |
human subjects | 4 |
virus dna | 4 |
mold infection | 4 |
final model | 4 |
emergency room | 4 |
southeast asia | 4 |
antibody assays | 4 |
demographic information | 4 |
previously healthy | 4 |
tract samples | 4 |
adaptive clinical | 4 |
basic military | 4 |
vitro data | 4 |
weekly surveillance | 4 |
students felt | 4 |
hospitalization surveillance | 4 |
menstrual period | 4 |
aspartate aminotransferase | 4 |
cber criteria | 4 |
epidemiological investigations | 4 |
sofa score | 4 |
covid patients | 4 |
laboratory staff | 4 |
internet connection | 4 |
health laboratory | 4 |
epidemic influenza | 4 |
lessons learned | 4 |
seeking care | 4 |
disease progression | 4 |
rna polymerase | 4 |
peak occurred | 4 |
droplet digital | 4 |
laboratory test | 4 |
independently associated | 4 |
imaging findings | 4 |
viral eradication | 4 |
dichotomous variables | 4 |
african americans | 4 |
higher proportion | 4 |
patient outcomes | 4 |
protease inhibitor | 4 |
immunosuppressed patients | 4 |
day window | 4 |
streptococcus pneumoniae | 4 |
patients presented | 4 |
serum samples | 4 |
rate ratio | 4 |
mycoplasma pneumoniae | 4 |
first trimester | 4 |
severe sars | 4 |
improve patient | 4 |
false negative | 4 |
san antonio | 4 |
require hospitalization | 4 |
serotype shift | 4 |
pathogen detection | 4 |
virus replication | 4 |
patients admitted | 4 |
comprehensive stewardship | 4 |
multiplex respiratory | 4 |
medical staff | 4 |
ed visits | 4 |
anxiety prevalence | 4 |
bactrian camels | 4 |
influenza testing | 4 |
mortality among | 4 |
prevalence setting | 4 |
greater proportion | 4 |
fungal disease | 4 |
unclear whether | 4 |
united kingdom | 4 |
assess whether | 4 |
data sources | 4 |
pilot study | 4 |
ethics committee | 4 |
closely related | 4 |
chronic comorbidities | 4 |
appropriate use | 4 |
health record | 4 |
descriptive study | 4 |
ipc team | 4 |
rural thailand | 4 |
hospitalized adults | 4 |
igg mg | 4 |
dna level | 4 |
health authorities | 4 |
diagnostic criteria | 4 |
last days | 4 |
breastfeeding patients | 4 |
secondary hlh | 4 |
possible covid | 4 |
clinical microbiology | 4 |
organ dysfunction | 4 |
remains unclear | 4 |
june th | 4 |
received either | 4 |
physical exam | 4 |
patients years | 4 |
early reports | 4 |
serum creatinine | 4 |
glomerular filtration | 4 |
emerging viral | 4 |
pneumonia admissions | 4 |
antiviral agents | 3 |
disseminated intravascular | 3 |
end points | 3 |
immunogenicity analyses | 3 |
laboratory network | 3 |
grant number | 3 |
accurately characterize | 3 |
time polymerase | 3 |
testing among | 3 |
radiographic evidence | 3 |
slightly increased | 3 |
positive serology | 3 |
gov nct | 3 |
center cohort | 3 |
systematic analysis | 3 |
web server | 3 |
fungal infection | 3 |
risk assessment | 3 |
clinical manifestations | 3 |
drug trials | 3 |
aged years | 3 |
detectable levels | 3 |
anxiety scale | 3 |
intravascular coagulation | 3 |
studies conducted | 3 |
kdigo criteria | 3 |
marrow transplant | 3 |
receptor binding | 3 |
specific comorbidities | 3 |
early severe | 3 |
testing resources | 3 |
rhinovirus positive | 3 |
patient satisfaction | 3 |
acute illness | 3 |
occupational exposure | 3 |
real time | 3 |
ethnic disparities | 3 |
observational cohort | 3 |
lower likelihood | 3 |
southern nepal | 3 |
pui work | 3 |
ofy sha | 3 |
lymphohistiocytosis hemophagocytic | 3 |
untreated groups | 3 |
future studies | 3 |
lower frequency | 3 |
panel test | 3 |
early phase | 3 |
analysis using | 3 |
crowded places | 3 |
positive nats | 3 |
study group | 3 |
optimal dosing | 3 |
multivariable analysis | 3 |
may th | 3 |
white blood | 3 |
virus testing | 3 |
high sensitivity | 3 |
us centers | 3 |
population level | 3 |
higher viral | 3 |
relatively short | 3 |
prevalence area | 3 |
genmark dx | 3 |
composite endpoint | 3 |
clinical diagnostics | 3 |
sari patients | 3 |
end point | 3 |
male genital | 3 |
younger age | 3 |
persistent low | 3 |
rheumatoid arthritis | 3 |
virus season | 3 |
specialized group | 3 |
high hiv | 3 |
drivethrough screening | 3 |
short exposures | 3 |
increased adjusted | 3 |
mild symptoms | 3 |
included age | 3 |
study include | 3 |
rating anxiety | 3 |
hev rna | 3 |
mf adjuvanted | 3 |
high rate | 3 |
outpatient management | 3 |
blood samples | 3 |
rsv peak | 3 |
ordinal scale | 3 |
china clinical | 3 |
hiv prevalence | 3 |
racially diverse | 3 |
ast times | 3 |
king abdulaziz | 3 |
epa list | 3 |
supplementary material | 3 |
day followed | 3 |
weeks gestation | 3 |
vast majority | 3 |
vomc follow | 3 |
experimental infection | 3 |
clinical disease | 3 |
seqirus inc | 3 |
matched pairs | 3 |
study clinical | 3 |
sars patients | 3 |
anc cells | 3 |
statin therapy | 3 |
ppe supply | 3 |
two groups | 3 |
fu period | 3 |
invasive mold | 3 |
swabs collected | 3 |
mean age | 3 |
prior mo | 3 |
common viral | 3 |
influenza treatment | 3 |
wilcoxon rank | 3 |
test abnormalities | 3 |
emergency preparedness | 3 |
pulmonary function | 3 |
beyond days | 3 |
clinical research | 3 |
dependent rna | 3 |
asymptomatic individuals | 3 |
adults aged | 3 |
patients identified | 3 |
given time | 3 |
scrub typhus | 3 |
interferon beta | 3 |
medical evaluation | 3 |
specimens tested | 3 |
higher severity | 3 |
whether sars | 3 |
four human | 3 |
commonly reported | 3 |
study protocols | 3 |
low viral | 3 |
exposure history | 3 |
imported group | 3 |
enrollment period | 3 |
direct comparison | 3 |
positive covid | 3 |
provided written | 3 |
legally authorized | 3 |
moderate outcome | 3 |
among older | 3 |
early intervention | 3 |
associated lower | 3 |
obstructive lung | 3 |
potential covid | 3 |
direct patient | 3 |
demonstrate efficacy | 3 |
swab sample | 3 |
marshfield clinic | 3 |
surrogate marker | 3 |
cti recipients | 3 |
enrolled patients | 3 |
data crawling | 3 |
step rt | 3 |
basic training | 3 |
joint base | 3 |
per day | 3 |
vaccine groups | 3 |
residency program | 3 |
mycoses study | 3 |
male sex | 3 |
viral coinfections | 3 |
performed metagenomic | 3 |
considered positive | 3 |
related symptoms | 3 |
statistically associated | 3 |
without respiratory | 3 |
program director | 3 |
determined using | 3 |
help clinicians | 3 |
filtration rate | 3 |
robust antibody | 3 |
identify patients | 3 |
treating physician | 3 |
vaccine program | 3 |
voluntary survey | 3 |
prescribing antibiotics | 3 |
chmp criterion | 3 |
term outcomes | 3 |
fetal growth | 3 |
solicited systemic | 3 |
fewer patients | 3 |
liver disease | 3 |
health conditions | 3 |
serious adverse | 3 |
testing may | 3 |
age adults | 3 |
influenza diagnosis | 3 |
potential risk | 3 |
transaminase levels | 3 |
icu referral | 3 |
chloroquine phosphate | 3 |
adjuvanted cell | 3 |
hev igg | 3 |
range iqr | 3 |
mechanistic models | 3 |
year medical | 3 |
postpartum women | 3 |
clinical laboratory | 3 |
actively recruiting | 3 |
whither infectious | 3 |
antibody classes | 3 |
elderly adults | 3 |
ad vs | 3 |
multivariate analysis | 3 |
mg per | 3 |
thermocycling conditions | 3 |
related clinical | 3 |
san diego | 3 |
sexually transmitted | 3 |
ranging study | 3 |
allowed us | 3 |
consider cytokine | 3 |
study vaccine | 3 |
systematic literature | 3 |
correct responses | 3 |
challenges associated | 3 |
testing options | 3 |
decompensated liver | 3 |
infection may | 3 |
time bias | 3 |
influenza surveillance | 3 |
also described | 3 |
composite outcome | 3 |
secondary outcome | 3 |
vitro efficacy | 3 |
authorized representative | 3 |
currently experiencing | 3 |
relevant differences | 3 |
study cohort | 3 |
use app | 3 |
alanine aminotransferase | 3 |
appropriate ppe | 3 |
lower dose | 3 |
oral secretions | 3 |
fda approval | 3 |
decreased antibiotic | 3 |
local disease | 3 |
resource allocation | 3 |
selective pressure | 3 |
hospitalized covid | 3 |
felt comfortable | 3 |
storm syndromes | 3 |
outcome data | 3 |
strongly agreeing | 3 |
published reports | 3 |
overall vomc | 3 |
years ago | 3 |
central laboratory | 3 |
recall bias | 3 |
sufficient information | 3 |
including low | 3 |
first reported | 3 |
infected persons | 3 |
positive pcr | 3 |
coronavirus oc | 3 |
patients aged | 3 |
consecutive patients | 3 |
disease outcome | 3 |
test group | 3 |
disease course | 3 |
nine patients | 3 |
hospitalization data | 3 |
response options | 3 |
antiviral use | 3 |
reduce antibiotic | 3 |
oropharyngeal swabs | 3 |
icu compared | 3 |
vaccine strain | 3 |
local ethical | 3 |
ppe availability | 3 |
unsolicited ae | 3 |
imaging results | 3 |
intravenous immunoglobulin | 3 |
ofv sha | 3 |
immune responses | 3 |
samples positive | 3 |
virus among | 3 |
recruit trainees | 3 |
influenza peak | 3 |
underlying diseases | 3 |
future study | 3 |
significant association | 3 |
functional status | 3 |
neutrophil count | 3 |
administered weeks | 3 |
ideal disinfectant | 3 |
prevalence among | 3 |
electronic diagnosis | 3 |
rp patients | 3 |
serological assays | 3 |
whose family | 3 |
observed disparities | 3 |
medical resources | 3 |
significantly lower | 3 |
medicine residency | 3 |
pneumonia clinical | 3 |
prolonged mp | 3 |
ct scan | 3 |
healthcare providers | 3 |
eventually discharged | 3 |
experiencing covid | 3 |
solely type | 3 |
new england | 3 |
reports grants | 3 |
emergency medicine | 3 |
compared using | 3 |
hlh secondary | 3 |
clinical experience | 3 |
hospitalized requiring | 3 |
potential exposure | 3 |
early detection | 3 |
second test | 3 |
public transport | 3 |
acquired hlh | 3 |
dining together | 3 |
ct value | 3 |
using real | 3 |
day vs | 3 |
remdesivir compared | 3 |
initial presentation | 3 |
pathogen identified | 3 |
diverse population | 3 |
vaccine production | 3 |
initial experience | 3 |
breastfeeding individuals | 3 |
training populations | 3 |
adult studies | 3 |
antibody persistence | 3 |
laboratory tests | 3 |
ofid ofv | 3 |
linear regression | 3 |
strategies will | 3 |
crp levels | 3 |
become available | 3 |
uninfected individuals | 3 |
prospective monitoring | 3 |
effective treatment | 3 |
additional respiratory | 3 |
official duties | 3 |
virus vaccine | 3 |
among persons | 3 |
antitumor therapies | 3 |
developed clinical | 3 |
quartile range | 3 |
disease among | 3 |
henter criteria | 3 |
factor analysis | 3 |
gilead sciences | 3 |
outpatient clinic | 3 |
required imv | 3 |
reporting observational | 3 |
adult respiratory | 3 |
among health | 3 |
subunit influenza | 3 |
first negative | 3 |
visiting others | 3 |
sars outbreak | 3 |
sectional online | 3 |
age population | 3 |
zoonotic coronaviruses | 3 |
samples spc | 3 |
approximately half | 3 |
following first | 3 |
may increase | 3 |
exclusion criterion | 3 |
census bureau | 3 |
epidemiological investigation | 3 |
possibly due | 3 |
seir modeling | 3 |
viral diagnostics | 3 |
adverse event | 3 |
hiv infection | 3 |
england journal | 3 |
upper range | 3 |
daily activity | 3 |
based sars | 3 |
time point | 3 |
nile virus | 3 |
lymphohistiocytosis associated | 3 |
negative patients | 3 |
behavioral aspects | 3 |
skilled nursing | 3 |
publicly available | 3 |
expression changes | 3 |
clinical sensitivity | 3 |
early nasopharyngeal | 3 |
rapid diagnostic | 3 |
oxygen saturation | 3 |
viral infection | 3 |
gault equation | 3 |
targeted chimeric | 3 |
dx esensor | 3 |
choice questions | 3 |
racial groups | 3 |
ofid ofy | 3 |
lung injury | 3 |
hlh may | 3 |
pneumonia patients | 3 |
many patients | 3 |
samples obtained | 3 |
geometric mean | 3 |
univariate logistic | 3 |
influenza infection | 3 |
census tract | 3 |
total number | 3 |
organ transplantation | 3 |
test performed | 3 |
attitudes towards | 3 |
receiving cd | 3 |
age populations | 3 |
adult cti | 3 |
also possible | 3 |
critical illness | 3 |
second sample | 3 |
reaction assay | 3 |
pandemic preparedness | 3 |
study reported | 3 |
seasonal influenza | 3 |
swine influenza | 3 |
specific adaptive | 3 |
pregnancy may | 3 |
became available | 3 |
important cause | 3 |
common respiratory | 3 |
among healthcare | 3 |
data collected | 3 |
laboratory data | 3 |
emory university | 3 |
remaining patients | 3 |
second doses | 3 |
derivation cohort | 3 |
hemagglutination inhibition | 3 |
values ranged | 3 |
standardized differences | 3 |
iu ml | 3 |
immunosuppressive drugs | 3 |
immunosuppressive regimen | 3 |
reaching statistical | 3 |
requiring invasive | 3 |
considered eligible | 3 |
least weeks | 3 |
clinical relevance | 3 |
inflammatory response | 3 |
receive remdesivir | 3 |
first patients | 3 |
higher population | 3 |
surveillance system | 3 |
severe community | 3 |
time report | 3 |
patient demographics | 3 |
sot patients | 3 |
high demand | 3 |
patient characteristics | 3 |
ha per | 3 |
suffolk county | 3 |
specific antibodies | 3 |
prevalent virus | 3 |
epidemic spread | 3 |
testing strategies | 3 |
perhaps due | 3 |
liver test | 3 |
following cti | 3 |
investigations performed | 3 |
clinical testing | 3 |
also suggests | 3 |
hiv prevention | 3 |
study also | 3 |
marrow transplantation | 3 |
positive patient | 3 |
rsv vaccine | 3 |
kuala lumpur | 3 |
adults presenting | 3 |
ip address | 3 |
medical research | 3 |
rhinovirus enterovirus | 3 |
individuals infected | 3 |
hemophagocytic syndrome | 3 |
asymptomatic subjects | 3 |
information system | 3 |
symptoms onset | 3 |
pregnant patients | 3 |
healthcare worker | 3 |
sars cov | 3 |
trained research | 3 |
higher prevalence | 3 |
chronic medical | 3 |
surveillance snapshot | 3 |
sustained infection | 3 |
th edition | 3 |
clinical significance | 3 |
safety seminar | 3 |
avoid crowded | 3 |
nasal swab | 3 |
disease burden | 3 |
significant effect | 3 |
surface disinfectants | 3 |
will also | 3 |
tested using | 3 |
detected among | 3 |
overall mortality | 3 |
clinical mngs | 3 |
baseline oxygen | 3 |
geographic residence | 3 |
psychological burden | 3 |
rhinovirus febrile | 3 |
transplant patients | 3 |
research center | 3 |
per minute | 3 |
ongoing covid | 3 |
testing criteria | 3 |
cases without | 3 |
clinical management | 3 |
term impact | 3 |
pathogen claim | 3 |
rsv incidence | 3 |
vaccine trials | 3 |
data set | 3 |
overall hospital | 3 |
associated respiratory | 3 |
interspecies transmission | 3 |
patients presenting | 3 |
meningoencephalitis diagnosed | 3 |
performed within | 3 |
saliva testing | 3 |
results reported | 3 |
hospital laboratory | 3 |
master mix | 3 |
information regarding | 3 |
abstracted data | 3 |
cases occurring | 3 |
currently applied | 3 |
predict discharge | 3 |
systemic corticosteroid | 3 |
total patients | 3 |
strongly disagree | 3 |
children hospitalized | 3 |
first case | 3 |
diabetes mellitus | 3 |
us healthcare | 3 |
camelus dromedarius | 3 |
negative results | 3 |
exposure prophylaxis | 3 |
weight gain | 3 |
peak month | 3 |
cti period | 3 |
active surveillance | 3 |
new data | 3 |
possible association | 3 |
based cohort | 3 |
propensity scores | 3 |
longitudinal study | 3 |
wide range | 3 |
well tolerated | 3 |
large cohort | 3 |
rsv infections | 3 |
normal daily | 3 |
tt virus | 3 |
provided informed | 3 |
antibody testing | 3 |
study results | 3 |
severe infections | 3 |
id core | 3 |
among hiv | 3 |
mycophenolate mofetil | 3 |
west nile | 3 |
antibiotic prophylaxis | 3 |
good outcome | 3 |
performance measures | 3 |
sicker patients | 3 |
behavior changes | 3 |
density per | 3 |
study groups | 3 |
days following | 3 |
infection occurred | 3 |
north west | 3 |
case subjects | 3 |
analyzed data | 3 |
dynamic response | 3 |
government hospitals | 3 |
high levels | 3 |
subjects enrolled | 3 |
medical student | 3 |
screen performed | 3 |
remaining active | 3 |
ribonucleic acid | 3 |
base san | 3 |
lung allograft | 3 |
odds ratios | 3 |
reduce risk | 3 |
easily accessible | 3 |
lung penetration | 3 |
geriatric units | 3 |
situation report | 3 |
data available | 3 |
randomised controlled | 3 |
trial enrollment | 3 |
discharged home | 3 |
modeling efforts | 3 |
increased rapidly | 3 |
separate study | 3 |
injection site | 3 |
included hospital | 3 |
unnecessary antibiotic | 3 |
disinfecting agents | 3 |
chronic hev | 3 |
vaccine introduction | 3 |
repeated testing | 3 |
service environment | 3 |
poisson regression | 3 |
pneumonia caused | 3 |
respiratory samples | 3 |
medical condition | 3 |
interim guidance | 3 |
authors declare | 3 |
pneumocystis jirovecii | 3 |
developing countries | 3 |
clinical recovery | 3 |
similar activity | 3 |
selecting disinfectants | 3 |
likely related | 3 |
associated infections | 3 |
near real | 3 |
pneumonia coronavirus | 3 |
transcriptase polymerase | 3 |
basic information | 3 |
subgroup analysis | 3 |
broad range | 3 |
severe hypogammaglobulinemia | 3 |
developing early | 3 |
symptoms consistent | 3 |
diagnostic testing | 3 |
vs usual | 3 |
molecular diagnosis | 3 |
standards currently | 3 |
reported systemic | 3 |
rp test | 3 |
emerging respiratory | 3 |
study using | 3 |
viral transmission | 3 |
cutaneous vasculitis | 3 |
ppe use | 3 |
mean ebv | 3 |
saliva specimen | 3 |
disease outcomes | 3 |
infection preventionists | 3 |
inflammatory drugs | 3 |
enrollment encounter | 3 |
surgical masks | 3 |
overall prevalence | 3 |
complete viral | 3 |
diagnostic panel | 3 |
antibiotic dose | 3 |
isolation criteria | 3 |
recovery rct | 3 |
african countries | 3 |
mild covid | 3 |
coexisting medical | 3 |
army trainees | 3 |
gastrointestinal illness | 3 |
several years | 3 |
attributable fraction | 3 |
early recognition | 3 |
cancer center | 3 |
periodic screening | 3 |
permissive host | 3 |
respiratory panels | 3 |
multicenter study | 3 |
study assessing | 3 |
patient cases | 3 |
higher frequency | 3 |
dna virus | 3 |
outbreak response | 2 |
military basic | 2 |
purchase availability | 2 |
varying degrees | 2 |
ehrlichiosis ehrlichiosis | 2 |
new virus | 2 |
patients positive | 2 |
rapid progression | 2 |
america guidelines | 2 |
trend towards | 2 |
qx droplet | 2 |
without reaching | 2 |
every day | 2 |
demographic data | 2 |
differential impact | 2 |
immune markers | 2 |
treat influenza | 2 |
diagnose covid | 2 |
vaccine type | 2 |
prevention behaviors | 2 |
healthy volunteers | 2 |
collected data | 2 |
genomic characterisation | 2 |
reactions included | 2 |
greater density | 2 |
induced hlh | 2 |
concomitant shedding | 2 |
cti hypogammaglobulinemia | 2 |
control committees | 2 |
immortal time | 2 |
associated coronavirus | 2 |
potential impact | 2 |
cancer invasive | 2 |
study persistence | 2 |
also performed | 2 |
cell immunotherapy | 2 |
np swabs | 2 |
community acquired | 2 |
training program | 2 |
critical cases | 2 |
days later | 2 |
via data | 2 |
used clinically | 2 |
huanan seafood | 2 |
review boards | 2 |
subsequent infant | 2 |
haemophagocytic lymphohistiocytosis | 2 |
following criteria | 2 |
audit tool | 2 |
healthy patients | 2 |
steroid therapy | 2 |
attending physicians | 2 |
unique expertise | 2 |
possible addition | 2 |
temporal dynamics | 2 |
profile reported | 2 |
within weeks | 2 |
disease divisions | 2 |
eligibility criteria | 2 |
cox models | 2 |
may provide | 2 |
testing using | 2 |
main cause | 2 |
respiratory droplets | 2 |
abdulaziz city | 2 |
wechat moments | 2 |
significant predictors | 2 |
reported race | 2 |
different car | 2 |
query blastn | 2 |
supply shortages | 2 |
cb idp | 2 |
adult rsv | 2 |
pregnancy test | 2 |
young men | 2 |
per liter | 2 |
proactive screening | 2 |
viral culture | 2 |
two quaternary | 2 |
larger study | 2 |
disease transmission | 2 |
surgical mask | 2 |
fidelity kit | 2 |
regulatory authorities | 2 |
primers used | 2 |
burdens among | 2 |
fell outside | 2 |
incubation time | 2 |
serology tests | 2 |
hit hubei | 2 |
diseases fellows | 2 |
tacrolimus level | 2 |
selected days | 2 |
respiratory coronavirus | 2 |
months old | 2 |
previously identified | 2 |
department visits | 2 |
patient willingness | 2 |
study arm | 2 |
i ozsz | 2 |
resolve cases | 2 |
fulldose group | 2 |
including sars | 2 |
substantial number | 2 |
natal province | 2 |
hopkins university | 2 |
whether participants | 2 |
related viruses | 2 |
included post | 2 |
antibiotic guide | 2 |
collected within | 2 |
wisconsin institutional | 2 |
common comorbidities | 2 |
cohort members | 2 |
acute gastrointestinal | 2 |
collected specimens | 2 |
testing strategy | 2 |
primary genetic | 2 |
international society | 2 |
individual behavioral | 2 |
secondary hemophagocytic | 2 |
highly acceptable | 2 |
current readiness | 2 |
symptoms reported | 2 |
illness molecular | 2 |
predicting disease | 2 |
specimens collected | 2 |
neither agree | 2 |
using data | 2 |
healthcare reform | 2 |
house staff | 2 |
umbilical cord | 2 |
contributing atopic | 2 |
initially developed | 2 |
xzdh yum | 2 |
hospitalized pneumonia | 2 |
large multicenter | 2 |
per study | 2 |
death per | 2 |
also unable | 2 |
abbott laboratories | 2 |
cytomegalovirus dna | 2 |
hospital infection | 2 |
clinical exclusion | 2 |
prock co | 2 |
active learning | 2 |
incarcerated hernia | 2 |
center study | 2 |
epa registration | 2 |
radio buttons | 2 |
increased susceptibility | 2 |
vaccines ltd | 2 |
antibiotic recommendations | 2 |
significant af | 2 |
likely diagnosis | 2 |
ordered list | 2 |
seminal fluid | 2 |
second dose | 2 |
required icu | 2 |
treated case | 2 |
preparedness guide | 2 |
mainland china | 2 |
defined according | 2 |
rejection events | 2 |
maternal body | 2 |
among army | 2 |
multiplex assay | 2 |
available literature | 2 |
potential bias | 2 |
adequate disinfecting | 2 |
pubmed medline | 2 |
cdc guidelines | 2 |
high volume | 2 |
multidrug resistance | 2 |
mini kit | 2 |
stage renal | 2 |
nassau county | 2 |
expert opinion | 2 |
medication adherence | 2 |
third trimester | 2 |
rural nepal | 2 |
estimated prevalence | 2 |
body temperature | 2 |
differences across | 2 |
global response | 2 |
susceptibility results | 2 |
pathogen analysis | 2 |
patient age | 2 |
molecular diagnostics | 2 |
primate model | 2 |
screening days | 2 |
unique impact | 2 |
ha antigen | 2 |
cystic fibrosis | 2 |
prolonged corticosteroid | 2 |
new evidence | 2 |
fungal prophylaxis | 2 |
pediatric emergency | 2 |
attenuated willingness | 2 |
bowel obstruction | 2 |
education level | 2 |
multiple small | 2 |
health records | 2 |
remdesivir within | 2 |
across multiple | 2 |
associated hospitalizations | 2 |
limited resources | 2 |
tumor necrosis | 2 |
received treatment | 2 |
vs post | 2 |
important step | 2 |
group stopped | 2 |
vaccines established | 2 |
proper hand | 2 |
nasal secretion | 2 |
probe sequences | 2 |
practical score | 2 |
evaluation research | 2 |
within meter | 2 |
vs days | 2 |
included additional | 2 |
included viral | 2 |
high fidelity | 2 |
allostatic load | 2 |
unbiased metagenomic | 2 |
hiv status | 2 |
identified cases | 2 |
efficacy data | 2 |
rickettsia japonica | 2 |
adverse reactions | 2 |
clinical specimens | 2 |
diagnostic terms | 2 |
decreased significantly | 2 |
previously demonstrated | 2 |
leukocyte count | 2 |
severe infectious | 2 |
patient health | 2 |
subjects died | 2 |
subjective fever | 2 |
care facility | 2 |
hospital leadership | 2 |
trial participants | 2 |
antibiotic regimens | 2 |
mechanically ventilated | 2 |
testing alone | 2 |
important learning | 2 |
although specific | 2 |
hematopoietic cell | 2 |
patients remain | 2 |
dropout rate | 2 |
improved mortality | 2 |
detected influenza | 2 |
hrv detected | 2 |
based study | 2 |
ferritin levels | 2 |
laboratoryconfirmed influenza | 2 |
negative sars | 2 |
oropharyngeal swab | 2 |
physician liaison | 2 |
willingness items | 2 |
affected province | 2 |
diagnostic tools | 2 |
convenience sample | 2 |
severe neurodegenerative | 2 |
established pharmacological | 2 |
obtain knowledge | 2 |
received rdv | 2 |
animal models | 2 |
first approved | 2 |
may represent | 2 |
intake visit | 2 |
improve diagnostic | 2 |
authors state | 2 |
service diagnosis | 2 |
superscript iii | 2 |
treatment protocol | 2 |
reduce antibiotics | 2 |
igg antibody | 2 |
care hospitals | 2 |
postintervention surveys | 2 |
hematological malignancy | 2 |
multiplex rt | 2 |
better use | 2 |
serology assays | 2 |
fas data | 2 |
individuals aged | 2 |
infection compared | 2 |
ver nrsz | 2 |
viral diseases | 2 |
every fu | 2 |
research nasal | 2 |
realtime reverse | 2 |
results due | 2 |
hydroxychloroquine monotherapy | 2 |
medical chart | 2 |
early period | 2 |
hcw wore | 2 |
closely monitored | 2 |
trials investigating | 2 |
regarding patient | 2 |
unfavorable clinical | 2 |
prime time | 2 |
also compared | 2 |
sociodemographic variables | 2 |
preventive behavior | 2 |
associated illness | 2 |
disease study | 2 |
patients treatment | 2 |
vitro antiviral | 2 |
decision support | 2 |
lung tissue | 2 |
independently reviewed | 2 |
confirmed case | 2 |
antigen tests | 2 |
diagnosed covid | 2 |
symptom severity | 2 |
pandemic cohort | 2 |
effector cells | 2 |
radiology results | 2 |
clinical laboratories | 2 |
large populations | 2 |
rapidly evolving | 2 |
cd cti | 2 |
leukemia treated | 2 |
large outbreaks | 2 |
negative pui | 2 |
basic view | 2 |
using microsoft | 2 |
median income | 2 |
severe ones | 2 |
adjuvant therapy | 2 |
coronavirus detection | 2 |
reported throughout | 2 |
individuals without | 2 |
year id | 2 |
influenza activity | 2 |
severe adverse | 2 |
published scores | 2 |
chronic disease | 2 |
guidance exists | 2 |
second trimester | 2 |
san francisco | 2 |
different influenza | 2 |
regional laboratory | 2 |
viral testing | 2 |
patients treated | 2 |
peer reviewed | 2 |
cell pool | 2 |
decreased alb | 2 |
proinflammatory cytokines | 2 |
system operating | 2 |
may impact | 2 |
respiratory secretions | 2 |
age hospitalized | 2 |
calendar month | 2 |
promising signals | 2 |
iv twice | 2 |
ongoing clinical | 2 |
laboratory throat | 2 |
disease epidemics | 2 |
additional individuals | 2 |
vomc care | 2 |
different specimen | 2 |
prospective single | 2 |
controlled study | 2 |
reported mental | 2 |
search tool | 2 |
bacterial pathogens | 2 |
like proteases | 2 |
new drug | 2 |
get involved | 2 |
chlamydophila pneumoniae | 2 |
developed acute | 2 |
human cytomegalovirus | 2 |
toxicity profile | 2 |
dose mf | 2 |
potential confounders | 2 |
mitigation strategies | 2 |
among men | 2 |
patient self | 2 |
days vs | 2 |
health threats | 2 |
deoxyribonucleic acid | 2 |
positivity rates | 2 |
magpix instrument | 2 |
physical examination | 2 |
ad vaccines | 2 |
setting epidemiology | 2 |
oral mucosa | 2 |
global impact | 2 |
syndrome caused | 2 |
modelling study | 2 |
severe illness | 2 |
africa among | 2 |
responses may | 2 |
groups achieved | 2 |
upper limit | 2 |
improved survival | 2 |
study center | 2 |
recent advances | 2 |
fetal outcomes | 2 |
echovirus infection | 2 |
center institutional | 2 |
work force | 2 |
college station | 2 |
cell transplant | 2 |
testing modality | 2 |
risk comorbid | 2 |
pneumonia admitted | 2 |
sectional survey | 2 |
geospatial distribution | 2 |
calls weeks | 2 |
overall seasonal | 2 |
local clinical | 2 |
two study | 2 |
disinfectant products | 2 |
symptoms specifically | 2 |
causes substantial | 2 |
effective strategy | 2 |
training sites | 2 |
physician independently | 2 |
age appeared | 2 |
herpes zoster | 2 |
least dose | 2 |
receive payment | 2 |
common reasons | 2 |
rapid molecular | 2 |
pneumonia cases | 2 |
health workforce | 2 |
cell infusion | 2 |
requiring imv | 2 |
phylogenetic analysis | 2 |
introduced universal | 2 |
infections occurring | 2 |
adenovirus vaccine | 2 |
commonly detected | 2 |
alt xunl | 2 |
cell activity | 2 |
thrombotic thrombocytopenic | 2 |
young man | 2 |
ethical committee | 2 |
factors affecting | 2 |
ecologic niche | 2 |
pcr high | 2 |
increasing number | 2 |
specific antibiotics | 2 |
pediatric hematopoietic | 2 |
five response | 2 |
terminology criteria | 2 |
chloroquine effectively | 2 |
ongoing interventional | 2 |
without rhinovirus | 2 |
hazards preparedness | 2 |
inhaled steroids | 2 |
patients died | 2 |
complete description | 2 |
significantly increased | 2 |
arterial oxygen | 2 |
cord blood | 2 |
sahlgrenska university | 2 |
id remains | 2 |
dose ah | 2 |
diverse populations | 2 |
considered significant | 2 |
army medical | 2 |
nat tests | 2 |
final logistic | 2 |
gradually lowered | 2 |
well studied | 2 |
biological samples | 2 |
available case | 2 |
either ttv | 2 |
students surveyed | 2 |
hospital clinical | 2 |
provide consent | 2 |
potential conflict | 2 |
less practical | 2 |
subsequent test | 2 |
multiple influenza | 2 |
study site | 2 |
lower cost | 2 |
health scales | 2 |
ventilated patients | 2 |
became part | 2 |
observation data | 2 |
additional training | 2 |
airway pressure | 2 |
injury burdens | 2 |
cti risk | 2 |
medicine clinician | 2 |
breast milk | 2 |
nutritional status | 2 |
force available | 2 |
likely due | 2 |
experience within | 2 |
adenovirus type | 2 |
pregnancy maternal | 2 |
risk score | 2 |
pediatric intensive | 2 |
pretransplant evaluation | 2 |
except immune | 2 |
short supply | 2 |
coronavirus outbreak | 2 |
albert einstein | 2 |
poor weight | 2 |
therapeutic use | 2 |
risk children | 2 |
authors concluded | 2 |
th january | 2 |
less sensitive | 2 |
specific primers | 2 |
using pre | 2 |
respiratory swabs | 2 |
hev meningoencephalitis | 2 |
five days | 2 |
fact sheet | 2 |
monoclonal antibody | 2 |
changes induced | 2 |
cases included | 2 |
table presents | 2 |
including mumps | 2 |
recent study | 2 |
cmv mismatch | 2 |
empiric antimicrobial | 2 |
enterovirus infection | 2 |
multivariable cox | 2 |
care remains | 2 |
illness visit | 2 |
toward decreased | 2 |
emerging viruses | 2 |
availability increases | 2 |
including ppe | 2 |
childhood pneumonia | 2 |
maternal febrile | 2 |
hemorrhagic fever | 2 |
infection event | 2 |
patient wore | 2 |
significant proportion | 2 |
saliva samples | 2 |
phase i | 2 |
parallel sequencing | 2 |
received hydroxychloroquine | 2 |
pathogenic human | 2 |
disease consultation | 2 |
pacific islander | 2 |
preventive measures | 2 |
hospital setting | 2 |
control practices | 2 |
infection status | 2 |
generally demonstrate | 2 |
crp mg | 2 |
ttv replication | 2 |
days august | 2 |
screen testing | 2 |
time access | 2 |
among study | 2 |
following clinical | 2 |
necrotic lesions | 2 |
level modeling | 2 |
cut offs | 2 |
biomarkers predicting | 2 |
clinical efficacy | 2 |
hundred eighty | 2 |
gave birth | 2 |
blood cultures | 2 |
per week | 2 |
spike protein | 2 |
term follow | 2 |
suspended weekly | 2 |
multivariable models | 2 |
utilized data | 2 |
supporting evidence | 2 |
fever feverishness | 2 |
limited testing | 2 |
children infected | 2 |
luminex xtag | 2 |
patient populations | 2 |
package insert | 2 |
upper airway | 2 |
known infection | 2 |
chinese general | 2 |
higher dose | 2 |
point likert | 2 |
also divided | 2 |
training command | 2 |
will reduce | 2 |
active sars | 2 |
time constraints | 2 |
cough presentations | 2 |
racial minorities | 2 |
preexisting comorbidities | 2 |
age categories | 2 |
ethics review | 2 |
bioinformatics pipeline | 2 |
daily dosing | 2 |
health questionnaire | 2 |
negative result | 2 |
noninvasive ventilation | 2 |
online consent | 2 |
developed herpes | 2 |
hospitalization compared | 2 |
greater number | 2 |
students downloaded | 2 |
adults respiratory | 2 |
common data | 2 |
either duke | 2 |
two patients | 2 |
pcr rpcr | 2 |
highly dependent | 2 |
return visits | 2 |
method described | 2 |
patient gloves | 2 |
recent preventive | 2 |
study personnel | 2 |
infection associated | 2 |
symptoms compatible | 2 |
detailed clinical | 2 |
tocilizumab administration | 2 |
additional cases | 2 |
remdesivir died | 2 |
influenza data | 2 |
cells may | 2 |
subgroup echovirus | 2 |
effective surface | 2 |
infants year | 2 |
enrolling patients | 2 |
institute inc | 2 |
inappropriate use | 2 |
recent studies | 2 |
previously diagnosed | 2 |
quick turnaround | 2 |
including ph | 2 |
system leadership | 2 |
care delivery | 2 |
receptor antagonist | 2 |
among others | 2 |
median hospital | 2 |
min using | 2 |
severe forms | 2 |
practices among | 2 |
specimen collected | 2 |
influenza positive | 2 |
survey evaluating | 2 |
human data | 2 |
demonstrated improved | 2 |
cape town | 2 |
obtained data | 2 |
id work | 2 |
kidney dysfunction | 2 |
observational health | 2 |